Efficacy, Immunogenicity, and Safety Evaluation of an MF59 Adjuvanted Trivalent Influenza Virus Vaccine Compared to Non-adjuvanted Influenza: A Comprehensive Review in Older Adults and Children: Publication of this supplement was supported by Novartis Vaccines and Diagnostics, Inc., and Seqirus, Inc.

International Journal of Infectious Diseases
Volume 85, Supplement, S1-S38
https://www.ijidonline.com/issue/S1201-9712(19)X0015-6

 

Efficacy, Immunogenicity, and Safety Evaluation of an MF59 Adjuvanted Trivalent Influenza Virus Vaccine Compared to Non-adjuvanted Influenza: A Comprehensive Review in Older Adults and Children: Publication of this supplement was supported by Novartis Vaccines and Diagnostics, Inc., and Seqirus, Inc.
Open Access